SG Americas Securities LLC Has $112,000 Position in Definitive Healthcare Corp. (NASDAQ:DH)

SG Americas Securities LLC increased its holdings in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 44.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,189 shares of the company’s stock after buying an additional 8,387 shares during the period. SG Americas Securities LLC’s holdings in Definitive Healthcare were worth $112,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA increased its stake in shares of Definitive Healthcare by 36.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock valued at $27,058,000 after buying an additional 1,626,813 shares during the period. 272 Capital LP boosted its holdings in Definitive Healthcare by 74.8% in the third quarter. 272 Capital LP now owns 1,114,080 shares of the company’s stock valued at $4,980,000 after acquiring an additional 476,766 shares during the last quarter. State Street Corp increased its position in Definitive Healthcare by 29.4% during the 3rd quarter. State Street Corp now owns 1,399,729 shares of the company’s stock valued at $6,257,000 after purchasing an additional 317,952 shares during the period. JPMorgan Chase & Co. raised its holdings in Definitive Healthcare by 431.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 222,090 shares of the company’s stock worth $993,000 after purchasing an additional 180,323 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Definitive Healthcare in the 3rd quarter worth approximately $512,000. 98.67% of the stock is owned by institutional investors.

Insider Activity at Definitive Healthcare

In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total value of $211,500.00. Following the transaction, the insider now directly owns 433,830 shares in the company, valued at $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.84% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DH. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Barclays reiterated an “underweight” rating and issued a $4.00 target price on shares of Definitive Healthcare in a report on Monday, January 13th. Finally, Stephens assumed coverage on Definitive Healthcare in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price target on the stock. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Definitive Healthcare has a consensus rating of “Hold” and an average target price of $5.72.

Definitive Healthcare Stock Performance

NASDAQ DH opened at $5.24 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The company has a fifty day moving average price of $4.50 and a 200-day moving average price of $4.40. Definitive Healthcare Corp. has a 1 year low of $3.19 and a 1 year high of $10.62. The firm has a market cap of $605.32 million, a price-to-earnings ratio of -1.69, a PEG ratio of 3.94 and a beta of 1.45.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.